{"title":"Antibiotic prophylaxis may be still required among transperineal prostate biopsies of diabetics: a cohort study.","authors":"Feiyue Ma, Yu Zhang","doi":"10.3389/fmed.2025.1618631","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Transperineal prostate biopsy (TP-PB) is considered the gold standard for suspected prostate cancer patients. However, the rate of transperineal prostate biopsy-related urinary tract infections (UTIs) has been calculated to be as high as 3%. This study aimed to discuss the incidence of transperineal prostate biopsy -related infections among diabetic patients who underwent antibiotic prophylaxis (AP) or not.</p><p><strong>Methods: </strong>The monocentric, comparative, observational cohort study was carried out at Xiangshan County First People's Hospital Medical Health Group, China between January 2021 and January 2023. The study included 246 diabetic men suspected of having prostate cancer who underwent transperineal prostate biopsy. One group was transperineal prostate biopsy with no antibiotic prophylaxis (Group A-no AP, <i>n</i> = 120, 48.8%), and the other was given a 3 days of oral antibiotics (Group B-AP, <i>n</i> = 126, 51.2%). Data on primary symptoms, urine culture (UC), urinary tract infections incidence, and prostate biopsy -related sequela were gathered 2 weeks following the prostate biopsy.</p><p><strong>Results: </strong>A total of 246 patients were involved, including 120 in Group A (67.4 ± 7.2 years) and 126 in Group B (68.5 ± 7.0 years) (<i>p</i> = 0.215). Prostate-specific antigen (PSA) levels were 16.1 ± 23.8 vs. 15.9 ± 22.3 ng/ml (<i>p</i> = 0.942), and the prostate cancer detection rate was 58% vs. 57.5% (<i>p</i> = 0.847). The incidence of asymptomatic bacteriuria was significantly higher (8/120, 6.7%) in Group A vs. Group B (1/126, 0.8%) (RR 8.4, 95% CI: 1.1-72.5, <i>p</i> < 0.001). Similarly, urinary irritation symptoms occurred in 30/120 (25.0%) vs. 5/126 (4.0%) patients (RR 6.3, 95% CI: 3.0-21.6, <i>p</i> < 0.001), fever in 9/120 (7.5%) vs. 1/126 (0.8%) (RR 9.5, 95% CI: 1.3-81.3, <i>p</i> = 0.001), and UTIs in 5/120 (4.2%) vs. 1/126 (0.8%) (RR 5.3, 95% CI: 0.63-47.2, <i>p</i> = 0.001), respectively. Notably, sepsis was not detected in either group.</p><p><strong>Conclusion: </strong>Antibiotic prophylaxis could decrease the incidence of transperineal prostate biopsy-related infections among diabetic patients.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1618631"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271213/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1618631","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Transperineal prostate biopsy (TP-PB) is considered the gold standard for suspected prostate cancer patients. However, the rate of transperineal prostate biopsy-related urinary tract infections (UTIs) has been calculated to be as high as 3%. This study aimed to discuss the incidence of transperineal prostate biopsy -related infections among diabetic patients who underwent antibiotic prophylaxis (AP) or not.
Methods: The monocentric, comparative, observational cohort study was carried out at Xiangshan County First People's Hospital Medical Health Group, China between January 2021 and January 2023. The study included 246 diabetic men suspected of having prostate cancer who underwent transperineal prostate biopsy. One group was transperineal prostate biopsy with no antibiotic prophylaxis (Group A-no AP, n = 120, 48.8%), and the other was given a 3 days of oral antibiotics (Group B-AP, n = 126, 51.2%). Data on primary symptoms, urine culture (UC), urinary tract infections incidence, and prostate biopsy -related sequela were gathered 2 weeks following the prostate biopsy.
Results: A total of 246 patients were involved, including 120 in Group A (67.4 ± 7.2 years) and 126 in Group B (68.5 ± 7.0 years) (p = 0.215). Prostate-specific antigen (PSA) levels were 16.1 ± 23.8 vs. 15.9 ± 22.3 ng/ml (p = 0.942), and the prostate cancer detection rate was 58% vs. 57.5% (p = 0.847). The incidence of asymptomatic bacteriuria was significantly higher (8/120, 6.7%) in Group A vs. Group B (1/126, 0.8%) (RR 8.4, 95% CI: 1.1-72.5, p < 0.001). Similarly, urinary irritation symptoms occurred in 30/120 (25.0%) vs. 5/126 (4.0%) patients (RR 6.3, 95% CI: 3.0-21.6, p < 0.001), fever in 9/120 (7.5%) vs. 1/126 (0.8%) (RR 9.5, 95% CI: 1.3-81.3, p = 0.001), and UTIs in 5/120 (4.2%) vs. 1/126 (0.8%) (RR 5.3, 95% CI: 0.63-47.2, p = 0.001), respectively. Notably, sepsis was not detected in either group.
Conclusion: Antibiotic prophylaxis could decrease the incidence of transperineal prostate biopsy-related infections among diabetic patients.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world